The National Board of Examinations (NBE) has declared the results of the Fellowship Entrance Test (FET 2023). Candidates who appeared for the exam can download their results from the official website ...
ALAMEDA, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and NBE-Therapeutics today announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) ...
National Board of Examinations (NBE) has started the online application process for the Fellowship Entrance Test (FET 2021). Eligible and interested candidates will be able to apply for the test till ...
INGELHEIM, Germany & BASEL, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, ...
SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues development of two ADC products under the collaboration with NBE PRAGUE, Czech Republic, Dec. 10, 2020 (GLOBE ...
Stage-I– The Stage-I Examination shall be Computer Based Test (CBT) comprising of 200 Questions with maximum marks as 200. The duration of the objective type test shall be of 180 Minutes (Three Page 5 ...
The National Board of Examination (NBE) has announced the withheld result of 535 candidates who appeared for the FMGE (Screening Test), December 2019 session. The NBE had announced the result of FMGE ...
NEW DELHI: National Board of Examinations has released the Foreign Medical Graduate Examination (FMGE) result on its official website. Candidates, who appeared for the examination held on December 4, ...
Banque Misr and the National Bank of Egypt have raised the interest rate on a new triple savings certificate from 18.5 percent to 19.5 percent. Triple Savings Certificate from the National Bank of ...
Chairman of the National Bank of Egypt (NBE) Hisham Okasha and Chairman of China Development Bank (CDB) Hu Huaibang signed a loan agreement worth $700m. The loan targets the implementation of ...
The acquisition will enhance Boehringer Ingelheim’s cancer cell-directed therapies portfolio and will complement its existing capabilities in antigen discovery and antibody and T-cell engager ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results